Tumour and serum MGMT promoter methylation and protein expression in glioblastoma patients

Clinical and Translational Oncology

Volumn 13, Issue 9, 2011, Pages 677-685

  Balañá, Carmen ^a   Carrato, Cristina ^a   Ramírez, José Luis ^a   Cardona, Andrés Felipe ^a,b   Berdiel, Mireia ^a   Sánchez, José Javier ^c   Tarón, Miquel ^a   Hostalot, Cristina ^a   Musulen, Eva ^a   Ariza, Aurelio ^a   Rosell, Rafael ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b HOSPITAL UNIVERSITARIO FUNDACIÓN SANTA FE DE BOGOTÁ   (Colombia)

^c UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

Author keywords

Concordance; Glioblastoma; Immunohistochemistry; Methylation specifi c polymerase chain reaction (MSP); O 6 methylguanine DNA methyltransferase (MGMT); Serum; Survival; Tissue

Indexed keywords

CARMUSTINE; CISPLATIN; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; TEMOZOLOMIDE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN;

ADJUVANT THERAPY; ADULT; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; CPG ISLAND; DNA METHYLATION; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIMODALITY CANCER THERAPY; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PROGRESSION FREE SURVIVAL; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; AGED; BLOOD; BLOOD ANALYSIS; BRAIN TUMOR; CHEMISTRY; GENETICS; METABOLISM; MIDDLE AGED; MORTALITY; NEOPLASM; PHYSIOLOGY; SERUM; SURVIVAL; TISSUE MICROARRAY;

ADULT; AGED; BLOOD CHEMICAL ANALYSIS; BRAIN NEOPLASMS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA REPAIR ENZYMES; FEMALE; GLIOBLASTOMA; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS; PROMOTER REGIONS, GENETIC; RETROSPECTIVE STUDIES; SERUM; SURVIVAL ANALYSIS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEINS;

EID: 84855398150     PISSN: 1699048X     EISSN: 16993055     Source Type: Journal    
DOI: 10.1007/s12094-011-0714-x     Document Type: Article

References (36)

1. Bodell WJ, Aida T, Berger MS, Rosenblum ML (1986) Increased repair of O6-alkylguanine DNA adducts in glioma-derived human cells resistant to the cytotoxic and cytogenetic effects of 1,3- bis(2-chloroethyl)-1-nitrosourea. Carcinogenesis 7:879-883 (Pubitemid 17130499)
2. Colvin M, Hilton J (1981) Pharmacology of cyclophosphamide and metabolites. Cancer Treat Rep 65[Suppl 3]:89-95 (Pubitemid 13248878)
3. Margison GP, Povey AC, Kaina B, Santibanez Koref MF (2003) Variability and regulation of O6-alkylguanine-DNA alkyltransferase. Carcinogenesis 24:625-635
4. Esteller M, Garcia-Foncillas J, Andion E et al (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354
5. Citron M, Graver M, Schoenhaus M et al (1992) Detection of messenger RNA from O6-methylguanine- DNA methyltransferase gene MGMT in human normal and tumor tissues. J Natl Cancer Inst 84:337-340
6. Fornace AJ Jr, Papathanasiou MA, Hollander MC, Yarosh DB (1990) Expression of the O6-methylguanine- DNA methyltransferase gene MGMT in MER+ and MER- human tumor cells. Cancer Res 50:7908-7911
7. Costello JF, Futscher BW, Tano K et al (1994) Graded methylation in the promoter and body of the O6-methylguanine DNA methyltransferase (MGMT) gene correlates with MGMT expression in human glioma cells. J Biol Chem 269:17228-17237 (Pubitemid 24204047)
8. Esteller M, Hamilton SR, Burger PC et al (1999) Inactivation of the DNA repair gene O6-methylguanine- DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 59:793-797 (Pubitemid 29086728)
9. Silber JR, Bobola MS, Ghatan S et al (1998) O6-methylguanine-DNA methyltransferase activity in adult gliomas: relation to patient and tumor characteristics. Cancer Res 58:1068-1073 (Pubitemid 28182481)
10. Hegi ME, Diserens AC, Godard S et al (2004) Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clin Cancer Res 10:1871-1874 (Pubitemid 38375541)
11. Stupp R, Dietrich PY, Ostermann Kraljevic S et al (2002) Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide. J Clin Oncol 20:1375-1382 (Pubitemid 34177445)
12. Hegi ME, Diserens AC, Gorlia T et al (2005) MGMT gene silencing and benefi t from temozolomide in glioblastoma. N Engl J Med 352:997-1003 (Pubitemid 40349502)
13. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996 (Pubitemid 40349501)
14. Chang SM, Parney IF, Huang W et al (2005) Patterns of care for adults with newly diagnosed malignant glioma. JAMA 293:557-564 (Pubitemid 40171237)
15. Balana C, Capellades J, Teixidor P et al (2007) Clinical course of high-grade glioma patients with a "biopsy-only" surgical approach: a need for individualised treatment. Clin Transl Oncol 9:797-803
16. Chinot OL, Barrie M, Fuentes S et al (2007) Correlation between O6-methylguanine-DNA methyltransferase and survival in inoperable newly diagnosed glioblastoma patients treated with neoadjuvant temozolomide. J Clin Oncol 25:1470-1475 (Pubitemid 46733073)
17. Pollack IF, Hamilton RL, Sobol RW et al (2006) O6-methylguanine-DNA methyltransferase expression strongly correlates with outcome in childhood malignant gliomas: results from the CCG-945 Cohort. J Clin Oncol 24:3431-3437 (Pubitemid 46638900)
18. Brell M, Tortosa A, Verger E et al (2005) Prognostic significance of O6-methylguanine-DNA methyltransferase determined by promoter hypermethylation and immunohistochemical expression in anaplastic gliomas. Clin Cancer Res 11:5167-5174 (Pubitemid 41003702)
19. Rodriguez FJ, Thibodeau SN, Jenkins RB et al (2008) MGMT immunohistochemical expression and promoter methylation in human glioblastoma. Appl Immunohistochem Mol Morphol 16:59-65
20. Stroun M, Anker P, Lyautey J et al (1987) Isolation and characterization of DNA from the plasma of cancer patients. Eur J Cancer Clin Oncol 23:707-712 (Pubitemid 17119706)
21. Balana C, Ramirez JL, Taron M et al (2003) O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 9:1461-1468 (Pubitemid 36418402)
22. Weaver KD, Grossman SA, Herman JG (2006) Methylated tumor-specifi c DNA as a plasma biomarker in patients with glioma. Cancer Invest 24:35-40 (Pubitemid 43247271)
23. Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8:1277-1280 (Pubitemid 20195640)
24. - (2010) Neurosurgeons achieve world's fi rst delivery of intra-arterial bevacizumab directly into brain tumor of glioblastoma multiforme patients. Future Oncol 6:9
25. CBTRUS (2007) 2007-2008 Statistical report: primary brain tumors in the United States, Statistical report, 2000-2004 (years of data collected). CBTRUS, Hinsdale, IL, http://www.cbtrus.org/reports//2007-2008/2007report.pdf2007-2008
26. Stupp R, Hegi ME (2007) Methylguanine methyltransferase testing in glioblastoma: when and how? J Clin Oncol 25:1459-1460 (Pubitemid 46733069)
27. Hau P, Stupp R, Hegi ME (2007) MGMT methylation status: the advent of stratifi ed therapy in glioblastoma? Dis Markers 23:97-104 (Pubitemid 46333643)
28. Cankovic M, Mikkelsen T, Rosenblum ML, Zarbo RJ (2007) A simplifi ed laboratory validated assay for MGMT promoter hypermethylation analysis of glioma specimens from formalin-fi xed paraffi nembedded tissue. Lab Invest 87:392-397 (Pubitemid 46474563)
29. Maxwell JA, Johnson SP, Quinn JA et al (2006) Quantitative analysis of O6-alkylguanine-DNA alkyltransferase in malignant glioma. Mol Cancer Ther 5:2531-2539 (Pubitemid 44650917)
30. Preusser M, Charles Janzer R, Felsberg J et al (2008) Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. Brain Pathol 18:520-532
31. Leon SA, Shapiro B, Sklaroff DM, Yaros MJ (1977) Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res 37:646-650 (Pubitemid 8051621)
32. Mori T, O'Day SJ, Umetani N et al (2005) Predictive utility of circulating methylated DNA in serum of melanoma patients receiving biochemotherapy. J Clin Oncol 23:9351-9358
33. Wakabayashi T, Natsume A, Hatano H et al (2009) p16 promoter methylation in the serum as a basis for the molecular diagnosis of gliomas. Neurosurgery 64:455-461; discussion 461-452
34. Stroun M, Maurice P, Vasioukhin V et al (2000) The origin and mechanism of circulating DNA. Ann N Y Acad Sci 906:161-168 (Pubitemid 30255476)
35. Pisal N, Sindos M, Singer A (2003) Re: Assessment of plasma DNA levels, allelic imbalance, and CA 125 as diagnostic tests for cancer. J Natl Cancer Inst 95:331; author reply 331-332 (Pubitemid 36336484)
36. Brandsma D, Stalpers L, Taal W et al (2008) Clinical features, mechanisms, and management of pseudoprogression in malignant gliomas. Lancet Oncol 9:453-461 (Pubitemid 351597795)